Optimal Time to Start Peripheral Blood Stem Cell Collection in Children with High-Risk Solid Tumors

다국어 초록 (Multilingual Abstract)

In order to clarify the optimal timing for peripheral blood stem cell (PBSC) collection, PBSC collection records of 323 children who were scheduled to undergo autologous stem cell transplantation from two study periods differing in the timing of PBSC collection were analyzed. In the early study period (March 1998 to August 2007, n=198), PBSC collection was initiated when the peripheral WBC count exceeded 1,000/μL during recovery from chemotherapy. Findings in this study period indicated that initiation of PBSC collection at a higher WBC count might result in a greater CD34+ cell yield. Therefore, during the late study period (September 2007 to December 2012, n=125), PBSC collection was initiated when the WBC count exceeded 4,000/μL. Results in the late study period validated our conclusion from the early study period. Collection of a higher number of CD34+ cells was associated with a faster hematologic recovery after transplant in the late study period. Initiation of PBSC collection at WBC count>4,000/μL was an independent factor for a greater CD34+ cell yield. In conclusion, PBSC collection at a higher WBC count is associated with a greater CD34+ cell yield, and consequently a faster hematologic recovery after transplant.

참고문헌 (Reference)

1 Kletzel M, "Treatment of high-risk neuroblastoma with triple-tandem high-dose therapy and stem-cell rescue: results of the Chicago Pilot II Study" 20 : 2284-2292, 2002

2 Matthay KK, "Treatment of high-risk neuroblastoma with intensive chemotherapy, radiotherapy, autologous bone marrow transplantation, and 13-cis-retinoic acid: Children’s Cancer Group" 341 : 1165-1173, 1999

3 Siena S, "Therapeutic relevance of CD34 cell dose in blood cell transplantation for cancer therapy" 18 : 1360-1377, 2000

4 Flomenberg N, "The use of AMD3100 plus G-CSF for autologous hematopoietic progenitor cell mobilization is superior to G-CSF alone" 106 : 1867-1874, 2005

5 Sung KW, "Tandem high-dose chemotherapy and autologous stem cell transplantation in patients with high-risk neuroblastoma: results of SMC NB-2004 study" 48 : 68-73, 2013

6 Sung KW, "Reduced-dose craniospinal radiotherapy followed by tandem high-dose chemotherapy and autologous stem cell transplantation in patients with high-risk medulloblastoma" 15 : 352-359, 2013

7 Devine SM, "Rapid mobilization of CD34+ cells following administration of the CXCR4 antagonist AMD3100 to patients with multiple myeloma and non-Hodgkin’s lymphoma" 22 : 1095-1102, 2004

8 Kuittinen T, "Prediction of mobilisation failure in patients with non-Hodgkin’s lymphoma" 33 : 907-912, 2004

9 Gordan LN, "Poor mobilization of peripheral blood stem cells is a risk factor for worse outcome in lymphoma patients undergoing autologous stem cell transplantation" 44 : 815-820, 2003

10 DiPersio JF, "Plerixafor and G-CSF versus placebo and G-CSF to mobilize hematopoietic stem cells for autologous stem cell transplantation in patients with multiple myeloma" 113 : 5720-5726, 2009

11 DiPersio JF, "Phase III prospective randomized double-blind placebo-controlled trial of plerixafor plus granulocyte colony-stimulating factor compared with placebo plus granulocyte colony-stimulating factor for autologous stem-cell mobilization and transplantation for patients with non-Hodgkin’s lymphoma" 27 : 4767-4773, 2009

12 Hester J., "Peripheral blood stem cell collection: the interaction of technology, procedure, and biological factors" 23 : 125-132, 2000

13 Ho AD, "Optimal timing for collections of blood progenitor cells following induction chemotherapy and granulocyte-macrophage colony-stimulating factor for autologous transplantation in advanced breast cancer" 7 : 1738-1746, 1993

14 Berthold F, "Myeloablative megatherapy with autologous stem-cell rescue versus oral maintenance chemotherapy as consolidation treatment in patients with high-risk neuroblastoma: a randomised controlled trial" 6 : 649-658, 2005

15 Elias AD, "Mobilization of peripheral blood progenitor cells by chemotherapy and granulocyte-macrophage colony-stimulating factor for hematologic support after high-dose intensification for breast cancer" 79 : 3036-3044, 1992

16 Pusic I, "Impact of mobilization and remobilization strategies on achieving sufficient stem cell yields for autologous transplantation" 14 : 1045-1056, 2008

17 George RE, "High-risk neuroblastoma treated with tandem autologous peripheral-blood stem cell-supported transplantation: long-term survival update" 24 : 2891-2896, 2006

18 손명희, "Hematologic Recovery after Tandem High-Dose Chemotherapy and Autologous Stem Cell Transplantation in Children with High-Risk Solid Tumors" 대한의학회 28 (28): 220-226, 2013

19 Carral A, "Factors influencing the collection of peripheral blood stem cells in patients with acute myeloblastic leukemia and non-myeloid malignancies" 27 : 5-12, 2003

20 Ikeda K, "Factors for PBPC collection efficiency and collection predictors" 31 : 245-259, 2004

21 Dreger P, "Effective mobilisation of peripheral blood progenitor cells with ‘Dexa-BEAM’ and G-CSF: timing of harvesting and composition of the leukapheresis product" 68 : 950-957, 1993

22 Klaus J, "Effect of CD34 cell dose on hematopoietic reconstitution and outcome in 508 patients with multiple myeloma undergoing autologous peripheral blood stem cell transplantation" 78 : 21-28, 2007

23 Sugrue MW, "Characterization and outcome of “hard to mobilize”’ lymphoma patients undergoing autologous stem cell transplantation" 39 : 509-519, 2000

24 Mavroudis D, "CD34+ cell dose predicts survival, posttransplant morbidity, and rate of hematologic recovery after allogeneic marrow transplants for hematologic malignancies" 88 : 3223-3229, 1996

25 Weaver CH, "An analysis of engraftment kinetics as a function of the CD34 content of peripheral blood progenitor cell collections in 692 patients after the administration of myeloablative chemotherapy" 86 : 3961-3969, 1995

26 Calandra G, "AMD3100 plus G-CSF can successfully mobilize CD34+ cells from non-Hodgkin’s lymphoma, Hodgkin’s disease and multiple myeloma patients previously failing mobilization with chemotherapy and/or cytokine treatment: compassionate use data" 41 : 331-338, 2008